Evidence map›Paper›PMID 41132627›Full record

ArticleClinical case reports2025

Clinical Experience With Biologic Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis: A Case Report and Review of Literature.

Pandaramparambil Saidu Nazneen, Thinley Dorji, Sonam Yangzom, R Vijayalakshmi Natarajan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pandaramparambil Saidu NazneenDepartment of Internal Medicine Divisional Railway Hospital Ponmalai India.ORCID https://orcid.org/0000-0001-6579-1462
Thinley DorjiDepartment of Internal Medicine Central Regional Referral Hospital Gelephu Bhutan.ORCID https://orcid.org/0000-0003-4932-8704
Sonam YangzomDepartment of Radiodiagnosis and Imaging Central Regional Referral Hospital Gelephu Bhutan.ORCID https://orcid.org/0000-0002-7293-1117
R Vijayalakshmi NatarajanDepartment of Internal Medicine Divisional Railway Hospital Ponmalai India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biological agents are highly effective in preventing/minimizing disability related to multiple sclerosis. However, in resource-limited countries, the diagnosis and management of multiple sclerosis are limited by social and structural determinants of health. Support for patients to access these medicines through government schemes or insurance coverage is important in preventing disability.

Indexed as

autoimmune diseasesbiological therapydemyelinating diseaseshealthcare costsNatalizumabRituximab

Identifiers

PMID41132627
PMCPMC12540202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.